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Abstract
Background: Petroleum ether extracts of Viola websteri Hemsl (Violaceae) were reported to have
anti-plasmodial activity against Plasmodium falciparum in vitro, with this activity being largely
attributable to 6-(8'Z-pentadecenyl)-salicylic acid (6-SA).
Methods: The schizontocidal activity of 6-SA on early Plasmodium berghei infections was evaluated
in a four-day test. The possible 'repository' activity of 6-SA was assessed using the method
described by Peters. The median lethal dose (LD50) of 6-SA, when given intraperitoneally, was also
determined using uninfected ICR mice and the method of Lorke.
Results: In the present study, 6-SA was found to have anti-malarial activity in vivo, when tested
against P. berghei in mice. 6-SA at 5, 10 and 25 mg/kg·day exhibited a significant blood schizontocidal
activity in four-day early infections, repository evaluations and established infections with a
significant mean survival time comparable to that of the standard drug, chloroquine (5 mg/kg·day).
Conclusion: 6-SA possesses a moderate anti-malarial activity that could be exploited for malaria
therapy.
Background
Malaria is a major tropical disease caused by parasites and
is responsible for significant morbidity and mortality
worldwide [1]. There is currently a dramatic resurgence of
the disease because of the increasing resistance of the vec-
tors to insecticides and the progressive resistance of the
causative parasites, particularly Plasmodium falciparum, to
anti-malarial drugs [2]. Therefore, there is an urgent need
to discover and develop new, effective and safe drugs for
the treatment of this disease [3]. Malarial parasites and
plant plastids have several common pathways and func-
tions that are fundamentally different from the analogous
pathways and functions in humans and may therefore
make good targets for anti-malarial drugs [4]. In tradi-
tional medicine, Viola is used for the treatment of insect
infections, cancer, virus infection, and skin diseases [5]. A
previous study [6] revealed that the petroleum ether
extracts from dried whole parts of the 15 Viola genera
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screened, Viola websteri had inhibition values of 31.7 as
percentage of parasite inhibition at 25 mg/ml. Petroleum
ether extracts from Viola websteri were found to have anti-
plasmodial activity against P. falciparum in vitro, with this
activity being largely attributable to 6-SA (Figure 1)[7]. In
the present study, 6-SA was found to have anti-malarial




Isolation of 6-SA from the plant material was reported
previously [7]. The test compound was prepared by sus-
pending the 6-SA in saline containing 0.5% Tween-80.
Animals
As experimental hosts, 8-week-old outbred male ICR mice
were purchased from Japan SLC (Hamamatsu, Japan). The
animals were housed in standard cages, with standard
feed and water given ad libitum, and they were acclima-
tized for 10 days prior to the experiments. All animal
experiments were performed according to the guidelines
for animal experimentation, Sanbon Medical Center,
Wonkwang University.
Parasite inoculation
The malarial parasite used was a chloroquine-sensitive
strain of P. berghei (ATCC 50175; American Type Culture
Collection, Manassas, VA, US), which has been main-
tained by serial blood passage in mice. The inoculum con-
sisted of 5 × 107 Plasmodium berghei parasitized red blood
cells per ml. This was prepared by determining both the
percentage parasitaemia and the red blood cell count of
the donor mouse and diluting the blood with isotonic
saline in proportions indicated by both determinations.
Each mouse was inoculated on day 0, intraperitoneally,
with 0.2 ml of infected blood containing about 1 × 107 P.
berghei parasitized red blood cell. The LD50 of the com-
pound was determined using male ICR mice by intraperi-
toneal route using the method of Lorke et al [8].
Effect of 6-SA on established Plasmodium berghei infection in mice Figure 2
Effect of 6-SA on established Plasmodium berghei infection in mice. The experimental hosts were infected on day 0 
and 'treated' orally, with saline containing 0.5% Tween-80, 6-SA at 5, 10 or 25 mg/kg·day or chloroquine at 5 mg/kg·day, on 
days 3–7.
Structure of 6-SA isolated from Viola websteri Hemsl Figure 1
Structure of 6-SA isolated from Viola websteri Hemsl.
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Evaluation of schizontocidal activity on early infection (4-
day test)
The schizontocidal activity of 6-SA on early P. berghei
infections was evaluated in a four-day test [9]. For this test,
after determining the animal's percentage of parasitaemia
and erythrocyte count, blood from an infected donor
mouse was diluted with isotonic saline to obtain an inoc-
ulum containing 5 × 107 infected erythrocytes/ml. Thirty
ICR mice were then (at about 07.30 hours) inoculated
intraperitoneally with 0.2 ml of the inoculum before
being randomly divided into six equal treatment groups
of five mice each. Every morning (at 08.00–09.00 hours)
from the day of infection (day 0) to 3 days later (day 3),
each mouse was administered orally either 6-SA in 0.2 ml
saline containing 0.5% Tween-80 (at 5, 10 and 25 mg 6-
SA/kg·day), chloroquine in 0.2 ml saline containing
0.5% Tween-80 (at 5 mg chloroquine/kg·day) or 0.2 ml
saline containing 0.5% Tween-80. On day 4, 24 hours
after the last treatment, a thin smear was made from the
tail blood of each mouse and stained with Giemsa to
determine the percentage parasitaemia (by counting the
number of parasitized erythrocytes per 200 erythrocytes,
in random fields). For each group of mice treated with 6-
SA or chloroquine, the mean percentage chemosuppres-
sion was then calculated as 100 [(A-B)/A], where A was
the mean percentage parasitaemia of the mice 'treated'
only with saline containing 0.5% Tween-80 (the negative
controls) and B was the mean parasitaemia in the test
group.
Evaluation of the repository activity
The possible 'repository' activity of 6-SA was assessed
using the method described by Peters [10]. For this,
another six groups of mice (five per group) were treated
pre-infection, with 0.2 ml oral doses of 6-SA in saline con-
taining 0.5% Tween-80 (at 5, 10 or 25 mg/kg·day),
pyrimethamine in saline containing 0.5% Tween-80 (at
1.2 mg/kg·day) or saline containing 0.5% Tween-80, for
4 consecutive days (days 0–3). On day 4, the mice were
inoculated with P. berghei (as in the 4-day test) and on day
7 (72 hours post-infection) their parasitaemias were
assessed.
Evaluation of schizontocidal activity in established 
infection (Rane test)
To evaluate schizontocidal activity in established infec-
tion [11], the 4-day test was repeated but modified so that
the first treatment did not take place until 72 hours after
the mice had been infected, the mice were treated daily for
five (not four) days and parasitaemias were evaluated on
each day of treatment. In addition, mortality and weight
changes in the mice were followed-up for 30 days post-
infection (day 29) and the day-29 parasitaemias of the
survivors were evaluated. The median lethal dose (LD50)
of 6-SA, when given intraperitoneally, was also deter-
mined using uninfected ICR mice and the method of
Lorke [8].
Statistical analysis
Data were compared using Student's t tests, with a P value
of < 0.05 being considered statistically significant.
Results and Discussion
In both the four-day test and the test of repository activity,
oral 6-SA produced dose-dependent chemosuppression
(Table 1), with even the lowest dose tested (5 mg/kg·day)
causing significant reductions in parasitaemia (P < 0.05).
The highest dose of 6-SA tested (25 mg/kg·day) did not
do well enough compared with the lowest dose tested (5
mg/kg·day), and did not quite reach the level of chemo-
suppression seen with the drugs used as positive controls–
chloroquine at 5 mg/kg·day) or pyrimethamine at 1.2
mg/kg·day (Table 1). In the mice that were treated only
from 72 hours post-infection, daily oral doses of 6-SA or
chloroquine led to gradual reductions in parasitaemia
over time, whereas the parasitaemias in the negative-con-
trol mice increased with time (Figure 2). All the mice
administered with 6-SA showed a gradual decrease in
body weight from day 7, but this weight loss lasted only
for a few days, after which these mice gained weight daily.
Table 1: Blood schizontocidal activity of 6-SA, as measured against Plasmodium berghei in mice
Dose 4-day test Repository activity
Compound/Drug (mg/kg/day) Average % parasitaemia Average % suppression Average % parasitaemia Average % suppression
6-SA 5 43.4 ± 0.25* 25.4 34.3 ± 0.37* 41.0
10 21.5 ± 0.34* 63.0 17.4 ± 0.28* 70.1
25 19.3 ± 0.09* 66.8 10.4 ± 0.09* 82.1
Chloroquine 5 6.4 ± 0.13* 89.0 ND ND
Pyrimethamine 1.2 ND*** ND 4.9 ± 0.32* 91.5
Control (S.T.**) 0.2 ml 58.2 ± 0.23 - 4.9 ± 0.32* -
* Data are expressed as mean ± for five animals per group when compared with control. P < 0.05.
** S.T.: saline containing 0.5% Tween-80
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Mice in the negative-control group lost weight daily dur-
ing the follow-up period. One of the five mice adminis-
tered with 10 mg/kg·day 6-SA died before day 29 (on day
22), as did three of the five mice treated with 5 mg/kg·day
(on days 18, 19 and 25) and all five of the negative-con-
trol mice (on days 11~18). None of the mice given the
highest dose of 6-SA and none of those given chloroquine
died during the follow-up period. The mean survival
times of the mice administered 5, 10 or 25 mg/kg·day 6-
SA, chloroquine and saline containing 0.5% Tween-80
were 24.0, 27.6, 30.0, 30.0 and 15 days, respectively. The
mice still alive on day 29 (all of which had been treated
with 6-SA or chloroquine) were aparasitaemic. In the tests
of activity against established infections, the highest tested
doses of 6-SA appeared as effective as chloroquine in
terms of the day-7 parasitaemias (Figure 2) and day-29
survival.
In the toxicity tests, all the mice administered 6-SA at 5–
500 mg/kg exhibited insignificant signs of toxicity, rang-
ing from writhing and gasping (LD50 of >500 mg/kg) to
decreased respiratory rate, decreased limb tone, and
death. The LD50 was calculated to be >500 mg/kg. The
present results indicate that 6-SA possesses useful blood
schizontocidal when used at doses that cause no marked
toxicity in mice. Although the mechanism of action of this
compound has not been elucidated, 6-SA clearly merits
further investigation.
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